Please wait a minute...
文章检索
预防医学  2026, Vol. 38 Issue (1): 36-42    DOI: 10.19485/j.cnki.issn2096-5087.2026.01.007
  论著 本期目录 | 过刊浏览 | 高级检索 |
高血压患者肥胖类型与动脉粥样硬化性心血管疾病风险的关系研究
郭艳强1, 张丽1, 张兰2, 韩荣荣1
1.杭州市临平区疾病预防控制中心(杭州市临平区卫生监督所),浙江 杭州 311100;
2.杭州市临平区东湖街道社区卫生服务中心,浙江 杭州 311100
Association between types of obesity and atherosclerotic cardiovascular disease risk among hypertensive patients
GUO Yanqiang1, ZHANG Li1, ZHANG Lan2, HAN Rongrong1
1. Linping District Center for Disease Control and Prevention (Linping District Institute of Public Health Supervision), Hangzhou, Zhejiang 311100, China;
2. Donghu Street Community Health Service Center, Linping District, Hangzhou, Zhejiang 311100, China
全文: PDF(823 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨高血压患者肥胖类型与10年动脉粥样硬化性心血管疾病(ASCVD)风险的关系,为制定高血压患者ASCVD预防策略提供依据。方法 于2021年1月—12月,采用整群抽样方法抽取杭州市临平区3家社区卫生服务中心随访管理且完成健康体检的高血压患者为研究对象。通过健康体检资料收集基本信息、生活方式、疾病史、身高、体重、腰围和血生化指标等。根据体重指数(BMI)和腰围评估,分为非肥胖、单纯全身型肥胖、单纯中心型肥胖和复合型肥胖4类。采用中国ASCVD风险预测研究模型评估10年ASCVD风险,分为低危、中危和高危。采用多因素logistic回归模型分析高血压患者不同肥胖类型与ASCVD风险的关系。结果 纳入高血压患者10 408例,年龄MQR)为68.00(10.00)岁。男性4 301例,占41.32%;女性6 107例,占58.68%。非肥胖、单纯全身型肥胖、单纯中心型肥胖和复合型肥胖分别3 635、2 378、450和3 945例,占34.93%、22.85%、4.32%和37.90%。ASCVD高危3 389例,占33.52%;非肥胖、单纯全身型肥胖、单纯中心型肥胖和复合型肥胖ASCVD高危分别为1 107、896、122和1 364例,占30.45%、37.68%、27.11%和34.58%。多因素logistic回归分析结果显示,校正性别、年龄、吸烟、饮酒、身体活动和糖尿病后,单纯全身型肥胖和复合型肥胖高血压患者ASCVD高危风险是非肥胖患者的1.383倍(95%CI:1.235~1.548)和1.225倍(95%CI:1.109~1.354)。结论 单纯全身型肥胖和复合型肥胖可增加高血压患者10年ASCVD高危风险,需加强高血压患者的体重和腰围综合管理以降低ASCVD发病风险。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
郭艳强
张丽
张兰
韩荣荣
关键词 动脉粥样硬化性心血管疾病肥胖类型高血压    
AbstractObjective To explore the association between types of obesity and 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among hypertensive patients, so as to provide the basis for formulating ASCVD prevention strategies for hypertensive patients. Methods From January to December 2021, hypertensive patients who were under follow-up management and completed health examinations at three community health service centers in Linping District, Hangzhou City were selected by a cluster sampling method. Basic information, lifestyle, disease history, height, weight, waist circumference (WC), and blood biochemical indicators were collected through health examination data. Based on assessments of body mass index (BMI) and WC, participants were categorized into four types: non-obese, general obesity only, central obesity only, and combined obesity. The Prediction for ASCVD risk in China (China-PAR) was used to assess 10-year ASCVD risk, which was categorized as low, moderate, and high risk. Multivariable logistic regression models were used to analyze the association between different types of obesity and ASCVD risk among hypertensive patients. Results A total of 10 408 hypertensive patients were included, with a median age of 68.00 (interquartile range, 10.00) years. There were 4 301 (41.32%) males and 6 107 (58.68%) females. The proportions of non-obese, general obesity only, central obesity only, and combined obesity were 34.93% (3 635 individuals), 22.85% (2 378 individuals), 4.32% (450 individuals), and 37.90% (3 945 individuals), respectively. There were 3 389 (33.52%) cases at high risk of ASCVD. Among them, high ASCVD risk was observed in 1 107 (30.45%), 896 (37.68%), 122 (27.11%), and 1 364 (34.58%) patients with non-obese, general obesity only, central obesity only, and combined obesity, respectively. Multivariable logistic regression analysis showed that after adjusting for gender, age, smoking, drinking, physical activity, and diabetes, the risk of high ASCVD in hypertensive patients with general obesity only and combined obesity was 1.383 times (95%CI: 1.235-1.548) and 1.225 times (95%CI: 1.109-1.354) that of non-obese hypertensive patients, respectively. Conclusions General obesity only and combined obesity can increase the 10-year high risk of ASCVD among hypertensive patients. It is necessary to strengthen comprehensive management of body weight and WC among hypertensive patients to reduce the risk of ASCVD.
Key wordsatherosclerotic cardiovascular disease    obesity type    hypertension
收稿日期: 2025-10-03      修回日期: 2026-01-07      出版日期: 2026-01-10
中图分类号:  R544.1  
  R54  
基金资助:杭州市临平区社会科学研究课题(Lpsk25B33)
作者简介: 郭艳强,本科,主管医师,主要从事社区综合防制管理工作
通信作者: 韩荣荣,E-mail:hrr0428@163.com   
引用本文:   
郭艳强, 张丽, 张兰, 韩荣荣. 高血压患者肥胖类型与动脉粥样硬化性心血管疾病风险的关系研究[J]. 预防医学, 2026, 38(1): 36-42.
GUO Yanqiang, ZHANG Li, ZHANG Lan, HAN Rongrong. Association between types of obesity and atherosclerotic cardiovascular disease risk among hypertensive patients. Preventive Medicine, 2026, 38(1): 36-42.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2026.01.007      或      https://www.zjyfyxzz.com/CN/Y2026/V38/I1/36
[1] 国家心血管病中心,中国心血管健康与疾病报告编写组,胡盛寿.中国心血管健康与疾病报告2024概要[J].中国循环杂志,2025,40(6):521-559.
[2] 淡亮星,谢华兵,刘志辉,等.全科医学视角下的动脉粥样硬化性心血管疾病一级预防[J].中华全科医师杂志,2025,24(6):656-662.
[3] KOSKINAS K C,VAN CRAENENBROECK E M,ANTONIADES C,et al.Obesity and cardiovascular disease:an ESC clinical consensus statement[J].Eur J Prev Cardiol,2025,32(3):184-220.
[4] 黄飞,朱进华,华召来,等.40~69岁居民肥胖类型与心血管危险因素的关联分析[J].现代预防医学,2023,50(13):2305-2310,2343.
[5] YANG X L,LI J X,HU D S,et al.Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population:the China-PAR project(prediction for ASCVD risk in China)[J].Circulation,2016,134(19):1430-1440.
[6] 李清霖,张宇清.国内外高血压指南心血管疾病风险评估系统综述[J/OL].中国医学前沿杂志(电子版),2020,12(7):33-40.
[7] 庞林鸿,赵雅静,朵林,等.云南省成年居民代谢综合征患病现状及其影响因素分析[J].中国公共卫生,2023,39(5):617-621.
[8] BULL F C,AL-ANSARI S S,BIDDLE S,et al.World Health Organization 2020 guidelines on physical activity and sedentary behaviour[J].Br J Sports Med,2020,54(24):1451-1462.
[9] 中国高血压修订委员会,高血压联盟,中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[10] 中华医学会糖尿病学分会.中国糖尿病防治指南(2024版)[J].中华糖尿病杂志,2025,17(1):16-139.
[11] 王增武,刘静,李建军,等.中国血脂管理指南(2023年)[J].中国循环杂志,2023,38(3):237-271.
[12] 中华人民共和国国家卫生和计划生育委员会.成人体重判定:WS/T 428—2013[S].北京:中国质检出版社,中国标准出版社,2013.
[13] 张海峰,靳迪,吕宪玉,等.北京某三甲医院体检人群不同肥胖类型与骨密度及握力的相关性分析[J].解放军医学院学报,2020,41(7):666-669,674.
[14] 中国心血管病风险评估和管理指南编写联合委员会.中国心血管病风险评估和管理指南[J].中华预防医学杂志,2019,53(1):13-35.
[15] JIA X J,HU C Y,XU Y,et al.Revisiting obesity thresholds for cardiovascular disease and mortality risk in Chinese adults:age-and gender-specific insights[J/OL].Cell Rep Med,2025,6(9)[2026-01-07].https://doi.org/10.1016/j.xcrm.2025.102309.
[16] 张迷磊,杨琼,陈海燕,等.肥胖类型与壮族中老年居民心血管疾病危险因素发生及聚集情况的分析[J].广西医科大学学报,2023,40(9):1564-1569.
[17] POWELL-WILEY T M,POIRIER P,BURKE L E,et al.Obesity and cardiovascular disease:a scientific statement from the American heart association[J].Circulation,2021,143(21):984-1010.
[18] 孔洁,黄攀登,任东静,等.中老年人群内脏脂肪代谢水平与心血管疾病的关联研究[J].预防医学,2025,37(12):1228-1232.
[19] TEMU T M,MACHARIA P,MTUI J,et al.Obesity and risk for hypertension and diabetes among Kenyan adults:Results from a national survey[J/OL].Medicine,2021,100(40)[2026-01-07].https://doi.org/10.1097/MD.0000000000027484.
[20] ROSS R,NEELAND I J,YAMASHITA S,et al.Waist circumference as a vital sign in clinical practice:a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity[J].Nat Rev Endocrinol,2020,16(3):177-189.
[21] MUSCOGIURI G,VERDE L,VETRANI C,et al.Obesity:a gender-view[J].J Endocrinol Investig,2024,47(2):299-306.
[22] ZHOU T,YUAN C X,SHEN C,et al.Association between physical activity and incident atherosclerotic cardiovascular disease is modified by predicted cardiovascular risk:The China-PAR project[J/OL].J Sport Health Sci,2025,14[2026-01-07].https://doi.org/10.1016/j.jshs.2025.101031.
[23] GOWER B,BLACKET C,GIRARD D,et al.Prospective associations between systolic blood pressure,serum cholesterol,and physical activity behaviour and the development of cardiovascular disease[J/OL].Prev Med,2024,183[2026-01-07].https://doi.org/10.1016/j.ypmed.2024.107958.
[24] GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations,1990-2021:a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet,2024,403(10440):2100-2132.
[1] 孟杨, 万金豹, 吴萃, 陈秋艳, 严青华, 程旻娜. 上海市农村高血压患者高血压知信行及家庭血压测量调查[J]. 预防医学, 2025, 37(7): 737-742.
[2] 李倩, 杨柏林, 陈积标, 尹寒露, 许祝平, 孟晓军. 无锡市50岁及以上HIV/AIDS抗病毒治疗病例自报慢性病资料分析[J]. 预防医学, 2025, 37(4): 390-394.
[3] 王启开, 弭亚楠, 刘好, 林嘉浩, 杨鑫源, 王越, 金千靖, 宋照猛. 高血压肾病患者膳食干预效果评价[J]. 预防医学, 2025, 37(4): 373-377.
[4] 缪彩云, 覃玉, 万亚男, 陈路路, 崔岚, 王小莉. 江苏省居民自测血压行为及影响因素分析[J]. 预防医学, 2025, 37(3): 223-227.
[5] 叶振淼, 张默涵, 樊丽辉, 谢轶敏, 姜雪霞, 郑宇航, 罗永园, 夏喆铮, 金茜, 孙倩. 超重、肥胖、中心性肥胖与高血压的关系研究[J]. 预防医学, 2025, 37(11): 1113-1118.
[6] 白开智, 章光明, 吴晓虹, 王小红, 徐则林, 庞志峰. 中国内脏脂肪指数预测高血压风险研究[J]. 预防医学, 2025, 37(11): 1119-1123.
[7] 龚海英, 薛凤玉, 刘晓芬, 邢瑞婷, 苗雨阳, 赵耀. 18~79岁居民高血压风险预测模型研究[J]. 预防医学, 2025, 37(10): 1075-1080.
[8] 金丹, 张开月, 王静. 家庭固体燃料使用与糖尿病、高血压风险的研究进展[J]. 预防医学, 2024, 36(8): 679-682.
[9] 陈德彬, 申锦玉. 厦门市居民慢性病患病情况调查[J]. 预防医学, 2024, 36(7): 622-625.
[10] 黄文, 汤佳良, 陈康康, 黄敏钢, 陈奇峰. 高血压合并糖尿病患者睡眠质量调查[J]. 预防医学, 2024, 36(4): 296-298,303.
[11] 高慧, 朱旭婷, 张磊, 夏庆华, 王英全, 张艳萍, 许姜敏, 施悦, 史午悦, 姜玉, 万金豹. 高血压发病年龄与糖尿病的关联研究[J]. 预防医学, 2024, 36(11): 921-925,930.
[12] 李晴, 潘宁宁, 刘敏, 李园, 张普洪, 白雅敏, 徐建伟. 正常高值血压、高血压与微量白蛋白尿的关联研究[J]. 预防医学, 2024, 36(11): 961-964.
[13] 王梦琴, 柴荟琳, 郭宇燕, 任敬娟, 梁瑞峰. 山西省农村居民高血压防治知识、态度、行为调查[J]. 预防医学, 2023, 35(7): 563-569.
[14] 沈益妹, 章奇, 朱新凤, 丁晶莹, 俞梅华. 湖州市血压控制未达标高血压患者慢性病共病及影响因素分析[J]. 预防医学, 2023, 35(6): 541-545,550.
[15] 张红, 胡志明, 潘晓锋, 朱梦胜, 戴伟丽, 谢伊丽, 诸建方. 社区高血压患者Triangle分层分级管理效果评价[J]. 预防医学, 2023, 35(4): 350-354,358.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed